Investigational drug · Phase 3
AK111
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Psoriasis, Skin Diseases, Ankylosing Spondylitis.
Phase 3Last checked: Nov 19, 2026Latest source record: Oct 16, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
0 still active
All registered trials
8
Any phase or sponsor naming "AK111"
First trial start
2023
Sep 22, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "AK111", any sponsor or status.
Conditions studied
As listed on its trial records.
- Psoriasis
- Skin Diseases
- Ankylosing Spondylitis
Approved drugs for the same conditions: Ankylosing spondylitis · Immunology and inflammation · Dermatology
Largest trials
Live from ClinicalTrials.gov: studies naming "AK111" as an intervention, largest first.
- A Phase III Study to Evaluate the Efficacy and Safety of AK111 in Subjects With Active Ankylosing SpondylitisPivotal-lookingCompleted
AkesoIndustry
NCT06378697 · 510 participants · Start Nov 22, 2023 · Primary completion Feb 19, 2025
Drug: AK111; Placebo+AK111 · For: Ankylosing Spondylitis
Sites: Bengbu, China; Hefei, China; Beijing, China · 60 sites in all
- To Evaluate the Efficacy and Safety of AK111 Injection in the Treatment of Moderate to Severe Plaque PsoriasisPivotal-lookingCompleted
AkesoIndustry
NCT06061471 · 454 participants · Start Sep 22, 2023 · Primary completion Dec 11, 2024
Drug: AK111; AK111 · For: Psoriasis; Skin Diseases
Sites: Bengbu, China; Wuhu, China; Chengde, China · 11 sites in all
- A Study to Evaluate the Efficacy and Safety of AK111 in Subjects With Moderate to Severe Plaque PsoriasisPivotal-lookingCompleted
AkesoIndustry
NCT06066125 · 351 participants · Start Mar 31, 2023 · Primary completion Aug 19, 2024
Drug: AK111; AK111 and 1 more · For: Psoriasis; Skin Diseases
Sites: Bengbu, China; Wannan, China; Chongqing, China · 34 sites in all
- A Phase 2 Study of Efficacy and Safety of AK111 in Subjects With Moderate-to-Severe PsoriasisPivotal-lookingCompleted
AkesoIndustry
NCT05096364 · 251 participants · Start Apr 28, 2021 · Primary completion Feb 3, 2023
Drug: AK111/Placebo · For: Psoriasis
Sites: Bengbu, China; Beijing, China; Guangzhou, China · 13 sites in all
- A Study to Evaluate the Efficacy and Safety of AK111 in Subjects With Active Ankylosing SpondylitisPivotal-lookingCompleted
AkesoIndustry
NCT05467995 · 125 participants · Start Jun 2, 2021 · Primary completion Apr 25, 2022
Drug: AK111; Placebo · For: Ankylosing Spondylitis
Sites: Bengbu, China; Beijing, China; Guangzhou, China · 15 sites in all
- A Study of AK111 in Healthy SubjectsCompleted
Akesobio Australia Pty LtdIndustry
NCT03622021 · 68 participants · Start Aug 14, 2018 · Primary completion Sep 9, 2019
Drug: AK111 or Placebo · For: Psoriasis
Sites: Christchurch, New Zealand
- A Clinical Study of AK139 in Healthy SubjectsNot yet recruiting
AkesoIndustry
NCT06947109 · 48 participants (planned) · Start May 6, 2025 · Primary completion Jan 30, 2026
Drug: Placebo; AK111 · For: Healthy Subjects
Sites: Hangzhou, China
AkesoIndustry
NCT05504317 · 48 participants · Start May 28, 2020 · Primary completion Mar 2, 2021
Drug: AK111; Placebo · For: Psoriasis
Sites: Bengbu, China; Beijing, China
Newest research
PubMed records naming it or its code names, newest first.
- Efficacy and safety of monoclonal antibody AK111 in the treatment of active ankylosing spondylitis: a randomised, double-blind, placebo-controlled, multicentre phase II clinical study.
Ye H, Liu S, Mei Y, et al. · Clin Exp Rheumatol 2026
- Efficacy, Safety and Pharmacokinetics of IL-17 Monoclonal Antibody Injection (AK111) in Patients with Moderate-to-Severe Plaque Psoriasis: A Randomized, Double-Blinded, Placebo-Controlled Phase Ib Multidose Escalation Clinical Study.
Jiang C, Zhou H, Zhang W, et al. · Dermatol Ther (Heidelb) 2023
- Population pharmacokinetic/pharmacodynamic analysis of AK111, an IL-17A monoclonal antibody, in subjects with moderate-to-severe plaque psoriasis.
Li Q, Qiao J, Jin H, et al. · Front Pharmacol 2022
- Microwave-assisted solution-phase synthesis and DART-mass spectrometric monitoring of a combinatorial library of indolin-2,3-dione schiff bases with potential antimycobacterial activity.
Aboul-Fadl T, Abdel-Aziz HA, Kadi A, et al. · Molecules 2011
Also in development for Psoriasis
- HSK44459Phase 39 trials
Haisco Pharmaceutical Group Co., Ltd. · Psoriasis, Idiopathic Pulmonary Fibrosis (IPF), Progressive Pulmonary Fibrosis
- TQH3906Phase 34 trials
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. · Psoriasis, Systemic Lupus Erythematosus, Psoriatic Arthritis
- IBI112Phase 32 trials
Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD. · Psoriasis
- Blinded EnvudeucitinibPhase 31 trial
Alumis Inc · Plaque Psoriasis, Psoriasis (PsO), Psoriasis
- CMAB015Phase 31 trial
Taizhou Mabtech Pharmaceutical Co.,Ltd · Psoriasis
- HPP737Phase 31 trial
Newsoara Biopharma Co., Ltd. · Psoriasis
- LZM012Phase 31 trial
Livzon Pharmaceutical Group Inc. · Psoriasis
- Open-Label EnvudeucitinibPhase 31 trial
Alumis Inc · Plaque Psoriasis, Psoriasis (PsO), Psoriasis
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.